Exploiting Tumour Hypoxia in Precision Medicine: Advancing Novel Prodrug Therapies for Pancreatic Cancer with a World-leading Canadian Cancer Centre

在精准医学中利用肿瘤缺氧：与世界领先的加拿大癌症中心共同推进胰腺癌的新型前药疗法

• 批准号: 132606
• 金额: $ 2.68万
• 依托单位: ONCOTHERICS LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132606
• 关键词: Exploiting; Tumour; Hypoxia; Precision; Medicine

The effectiveness of cancer therapy can be limited by barriers to drug penetration at the tumour and theharbouring of drug-resistant cells in poorly oxygenated or "hypoxic" tumour regions - these becomingsources of spread. The UK company Oncotherics has developed non-toxic drugs that are designed topenetrate into these difficult to treat regions, sense the low levels of oxygen and “activate” to kill theproblematic cancer cells. The challenge is highlighted by the treament resistance of pancreatic cancer withonly 1 in every 100 patients in England & Wales surviving their disease for more than 10 years with littleimprovment since the 1970s. Our key innovation is to link with a world-leading Cancer Centre in Canadato approach a clincal trial that exploits a ground-breaking imaging technology that will allow us to identifypancreatic cancer patients with hypoxic tumours for this targeted drug therapy. Funding will acceleratethis link with PMCC , increase the prospects for investor interest with entry into a $1.7bn global market,provide a route to regulatory approval and clinical adoption in cancer centres both in the UK & globally.

癌症治疗的有效性可能会受到肿瘤处药物渗透的障碍以及耐药细胞在氧合不良或“缺氧”肿瘤区域的庇护-这些扩散的危险来源的限制。英国Oncotherics公司已经开发出无毒药物，旨在渗透到这些难以治疗的区域，感知低水平的氧气并“激活”杀死有问题的癌细胞。胰腺癌的耐药性突出了这一挑战，在英格兰和威尔士，每100名患者中只有1人能存活10年以上，自20世纪70年代以来几乎没有改善。我们的关键创新是与加拿大一家世界领先的癌症中心建立联系，以进行一项临床试验，该试验利用了一种突破性的成像技术，使我们能够识别患有缺氧肿瘤的胰腺癌患者，以进行这种靶向药物治疗。资金将加速与PMCC的联系，增加投资者对进入17亿美元全球市场的兴趣，为英国和全球癌症中心的监管批准和临床采用提供途径。